Outcomes in Breast Cancer Patients Who Refuse Recommended Therapy

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD

May 26th 2025

ctDNA Analysis Shows Durvalumab/CRT Reduced Progression in Advanced Cervical Cancer

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Ashley Chan

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

The risk of progression was reduced with the use of durvalumab/CRT for advanced cervical cancer, according to an exploratory ctDNA analysis.

Rahul Banerjee, MD, FACP;Shernan Holtan, MD

March 3rd 2025

Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

Tony Berberabe, MPH

High Response Rates Seen with Fruquintinib Combo in HER2– Advanced Gastric/GEJ Cancer

The combination of olaparib and radium-223 improved rPFS in castration-resistant prostate cancer without prior docetaxel treatment or with fewer than 20 bone metastases.

Kyle Doherty

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Fruquintinib plus chemotherapy and a PD-1 inhibitor elicited an ORR of 80.0% with all partial responses in patients with treatment-naïve gastric/GEJ cancer.

Related Content

Gina Mauro

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD

May 26th 2025

ctDNA Analysis Shows Durvalumab/CRT Reduced Progression in Advanced Cervical Cancer

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Ashley Chan

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

The risk of progression was reduced with the use of durvalumab/CRT for advanced cervical cancer, according to an exploratory ctDNA analysis.

Rahul Banerjee, MD, FACP;Shernan Holtan, MD

March 3rd 2025

Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

Tony Berberabe, MPH

High Response Rates Seen with Fruquintinib Combo in HER2– Advanced Gastric/GEJ Cancer

The combination of olaparib and radium-223 improved rPFS in castration-resistant prostate cancer without prior docetaxel treatment or with fewer than 20 bone metastases.

Kyle Doherty